(Adds details, background, stock price)
May 28 Trimel Pharmaceuticals Corp said
its experimental sexual disorder drug increased the average
number of orgasms in women with an orgasmic disorder in a second
The company said its lowest tested dose of 0.6 mg of the
nasal drug Tefina showed a statistically significant increase,
compared with a placebo, in the number of orgasms in pre- and
post-menopausal patients with female orgasmic disorder.
The study, which tested three doses of the drug, enrolled
253 patients who were treated over 84 days in a home setting,
The company did not report the findings from the other two
tested doses of Tefina, a low-dose gel formulation of
Trimel reported in February 2012 that the drug improved the
occurrence of orgasms in a smaller mid-stage study conducted in
a hospital setting.
Trimel said on Wednesday that the drug improved sexual
functioning and satisfaction, and reduced distress. It was also
well-tolerated, with no serious adverse events reported.
Female orgasmic disorder, also known as anorgasmia, is
characterized by a delay, absence or reduced intensity of
orgasms, leading to distress.
There is no approved treatment for the condition, but
patients are often given hormone tablets and patches.
Trimel's stock closed at 70 Canadian cents on Tuesday on the
Toronto Stock Exchange.
(Reporting by Vrinda Manocha in Bangalore; Editing by Kirti
Pandey and Savio D'Souza)